BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 28569920)

  • 21. Combination antiplatelet treatment in coronary artery disease patients: A necessary evil or an overzealous practice?
    Alexopoulos D; Katogiannis K; Sfantou D; Lekakis J
    Platelets; 2018 May; 29(3):228-237. PubMed ID: 29022423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of GP IIb/IIIa receptor monoclonal antibody (7E3), heparin, and aspirin in an ex vivo canine arteriovenous shunt model of stent thrombosis.
    Makkar RR; Litvack F; Eigler NL; Nakamura M; Ivey PA; Forrester JS; Shah PK; Jordan RE; Kaul S
    Circulation; 1997 Feb; 95(4):1015-21. PubMed ID: 9054765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process.
    Hosokawa K; Ohnishi T; Fukasawa M; Kondo T; Sameshima H; Koide T; Tanaka KA; Maruyama I
    Microvasc Res; 2012 Mar; 83(2):154-61. PubMed ID: 22166857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo.
    Massberg S; Konrad I; Bültmann A; Schulz C; Münch G; Peluso M; Lorenz M; Schneider S; Besta F; Müller I; Hu B; Langer H; Kremmer E; Rudelius M; Heinzmann U; Ungerer M; Gawaz M
    FASEB J; 2004 Feb; 18(2):397-9. PubMed ID: 14656994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates.
    Marciniak SJ; Mascelli MA; Furman MI; Michelson AD; Jakubowski JA; Jordan RE; Marchese PJ; Frelinger AL
    Thromb Haemost; 2002 Jun; 87(6):1020-5. PubMed ID: 12083481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-GPVI Fab SAR264565 effectively blocks GPVI function in ex vivo human platelets under arterial shear in a perfusion chamber.
    Florian P; Wonerow P; Harder S; Kuczka K; Dubar M; Graff J
    Eur J Clin Pharmacol; 2017 Aug; 73(8):949-956. PubMed ID: 28523478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
    Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression.
    Scazziota A; Altman R; Rouvier J; Gonzalez C; Ahmed Z; Jeske WP; Walenga JM; Fareed J
    Thromb Res; 2000 Dec; 100(6):479-88. PubMed ID: 11152927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
    Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
    Nylander S; Wågberg F; Andersson M; Skärby T; Gustafsson D
    J Thromb Haemost; 2015 Aug; 13(8):1494-502. PubMed ID: 26096765
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor.
    Gerrits AJ; Jakubowski JA; Sugidachi A; Michelson AD; Frelinger AL
    J Thromb Haemost; 2017 May; 15(5):858-867. PubMed ID: 28092426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
    Perzborn E; Heitmeier S; Laux V
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):554-62. PubMed ID: 25848131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
    Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
    Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F; Rossi E; Pareti FI; Colli S; Tremoli E; Gallo L
    Haematologica; 2001 Feb; 86(2):192-8. PubMed ID: 11224490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice.
    Grüner S; Prostredna M; Koch M; Miura Y; Schulte V; Jung SM; Moroi M; Nieswandt B
    Blood; 2005 Feb; 105(4):1492-9. PubMed ID: 15507524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo.
    Schulz C; Konrad I; Sauer S; Orschiedt L; Koellnberger M; Lorenz R; Walter U; Massberg S
    Thromb Haemost; 2008 Jan; 99(1):190-5. PubMed ID: 18217153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Platelet collagen receptor Glycoprotein VI-dimer recognizes fibrinogen and fibrin through their D-domains, contributing to platelet adhesion and activation during thrombus formation.
    Induruwa I; Moroi M; Bonna A; Malcor JD; Howes JM; Warburton EA; Farndale RW; Jung SM
    J Thromb Haemost; 2018 Feb; 16(2):389-404. PubMed ID: 29210180
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
    Lecut C; Schoolmeester A; Kuijpers MJ; Broers JL; van Zandvoort MA; Vanhoorelbeke K; Deckmyn H; Jandrot-Perrus M; Heemskerk JW
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1727-33. PubMed ID: 15231520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.